TOP TEN perturbations for 1554781_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1554781_at
Selected probe(set): 233475_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1554781_at (233475_at) across 6674 perturbations tested by GENEVESTIGATOR:

colorectal cancer study 33 (adenocarcinoma; cecum) / normal cecum tissue

Relative Expression (log2-ratio):0.9948969
Number of Samples:3 / 2
Experimental colorectal cancer study 33 (adenocarcinoma; cecum)
Primary tumor samples derived from the cecum of patients with adenocarcinoma.
Control normal cecum tissue
Normal cecal tissue samples.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.90621567
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):0.8619385
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)

Relative Expression (log2-ratio):0.85335255
Number of Samples:5 / 3
Experimental engineered skin substitute study 2 (late)
Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.

pediatric septic shock study 3 (school-age; subclass A) / pediatric septic shock study 3 (school-age)

Relative Expression (log2-ratio):0.8156786
Number of Samples:6 / 22
Experimental pediatric septic shock study 3 (school-age; subclass A)
Whole blood samples obtained from school-age children (≥ 6 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Three children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (school-age)
Whole blood obtained from scholar age children (> 6 years of age) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. To determine survival rate, patients were followed for 28 days.

smoking study 13 (current smoker) / adenocarcinoma lung tissue (never smoker)

Relative Expression (log2-ratio):-0.81352234
Number of Samples:16 / 8
Experimental smoking study 13 (current smoker)
Lung tumor samples of current smokers diagnosed with lung adenocarcinoma.
Control adenocarcinoma lung tissue (never smoker)
Lung samples of never smokers diagnosed with lung adenocarcinoma.

smoking study 13 (former smoker) / adenocarcinoma lung tissue (never smoker)

Relative Expression (log2-ratio):-0.7885761
Number of Samples:23 / 8
Experimental smoking study 13 (former smoker)
Lung tumor samples of former smokers diagnosed with lung adenocarcinoma.
Control adenocarcinoma lung tissue (never smoker)
Lung samples of never smokers diagnosed with lung adenocarcinoma.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.72375774
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-0.7182951
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

engineered skin substitute study 2 (early) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):0.70143795
Number of Samples:6 / 2
Experimental engineered skin substitute study 2 (early)
Human skin substitutes tissue samples collected after 3 and 7 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.